MedTrace Logo

Umbrella Study for HIV Infected Adults Enrolled in NIAID-Funded Interleukin-2 Studies

NCT00311688 · Status: COMPLETED · Type: OBSERVATIONAL

Last updated 2021-11-01

No results posted yet for this study

Summary

Interleukin-2 (IL-2) is a protein found naturally in the blood that helps boost the immune system. The purpose of this study is to provide long-term treatment and monitoring of HIV infected people enrolled in NIAID-funded studies investigating the use of laboratory-made IL-2 for the treatment of HIV infection.

Conditions

  • HIV Infections

Interventions

DRUG

Interleukin-2

Biological response modifier in liquid form; dosage of drug will vary by study

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Richard T. Davey, Jr., MD, FACP · NIAID HIV Research Clinic, Laboratory of Immunoregulation, NIAID

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-12-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00311688 on ClinicalTrials.gov